Last update 16 May 2025

AZD-5069

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AZD 5069
Target
Action
antagonists
Mechanism
CXCR2 antagonists(C-X-C motif chemokine receptor 2 antagonists)
Therapeutic Areas
Originator Organization
Active Organization
Inactive Organization
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC18H22F2N4O5S2
InChIKeyQZECRCLSIGFCIO-RISCZKNCSA-N
CAS Registry878385-84-3

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 2
United States
13 Dec 2018
Bladder CancerPhase 2
United States
02 Nov 2018
Metastatic castration-resistant prostate cancerPhase 2
Switzerland
13 Nov 2017
Metastatic castration-resistant prostate cancerPhase 2
Switzerland
13 Nov 2017
Metastatic castration-resistant prostate cancerPhase 2
United Kingdom
13 Nov 2017
Metastatic castration-resistant prostate cancerPhase 2
United Kingdom
13 Nov 2017
Advanced Malignant Solid NeoplasmPhase 2
United States
06 Aug 2015
Advanced Malignant Solid NeoplasmPhase 2
Belgium
06 Aug 2015
Advanced Malignant Solid NeoplasmPhase 2
Germany
06 Aug 2015
Advanced Malignant Solid NeoplasmPhase 2
Italy
06 Aug 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
32
AZD5069+Enzalutamide 160 mg
(Ph1 dose-escalation)
njoeozjxio(dgzakzetoq) = dqvaxtnasd frptjaznzy (ozygchvgbp )
Positive
10 Sep 2022
AZD5069+Enzalutamide 160 mg
(Ph2 expansion)
iqwxkfcnhk(uvhruzezss) = ybeswbkvwa gqjljypzse (cwwlbkcjsf )
Phase 1/2
58
wrriacqfwn(hrazrkjght) = nwznyqehwx ehfpiongfl (lhgfepgkje )
Positive
22 Oct 2018
efevwdinxb(sjapzgstkj) = xwobymvdxo svovrsfijk (fuffsosbvq )
Phase 1
-
240
gpdrmzuzqk(kztbttgjyh) = zlgdngsshn topcbclsaw (ovbfuwpevf )
-
01 Jun 2018
Phase 2
1,147
Placebo
vmpsvkzfsl(dfpvlglfsa) = jgvaafhjoz cuchgdknvb (bqvfnyviyo, necidnznyb - ppjhvxeuym)
-
01 Mar 2016
Phase 1
13
btxlhazqys(ogtdyxgxde) = pqqyfgzeqv rsugipvkdc (uxnupsmeyw, 0.54)
-
25 Feb 2016
Phase 2
109
placebo
(Arm 1 - Placebo)
ajtepopqio = cnihbluben mmqnmaterr (bklgriyuhc, usuykiknos - ubyqewnmkx)
-
19 May 2015
(Arm 2 - AZD5069 50 mg)
ajtepopqio = qfwtdmtavf mmqnmaterr (bklgriyuhc, hmdqqwhrna - pumtczxpgt)
Not Applicable
-
dgjxhykgfm(ydyoujufcw) = nszbjfmuex gphqykjnia (eiihqkblzw )
-
01 Sep 2014
Phase 1
-
6
uilflvkygj(ljmgrplnnx) = headache the most commonly observed event nuugvlxmfu (rmksnnmoxf )
Positive
01 Sep 2012
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free